Immunotherapy for cancer is a forthcoming therapeutic option in cancer treatment. A variety of approaches, including adoptive cell transfer, adjuvant therapy, and monoclonal antibody therapy, are currently used as complementary or alternative cancer treatments. Since immunity against tumors is established as a result of complex interactions among tumors and immune cells, a theoretical framework to elucidate the dynamics of tumor killing by immune cells initiated by clinical intervention needs to be developed. We construct a simple mathematical model that describes the killing of tumors by T cells. We focus on a mathematical characterization of the effect of adoptive cell transfer therapy, the injection of a patient's own ex vivo activated T cells to initiate tumor immunity. On the basis of rigorous mathematical analyses and numerical computations, we provide biological interpretations for the possible outcomes of adoptive cell transfer under three different scenarios in terms of proliferation. In our modeling framework, adoptive cell transfer therapy can be understood as a driving force that potentially operates to shift the state of an immune response from inactive to active. On the other hand, our modeling framework suggests the possibility that a tumor can exploit a self-augmenting proliferation of T cells mediated by autocrine/paracrine signaling as an escape strategy from an immune response.
Introduction
The immune system is a self-defense mechanism that operates to eliminate an invasion of pathogens. T cells react specifically to a particular antigen bound to a major histocompatibility complex (MHC) class II molecule that is recognizable by T cell receptors. Owing to the education process in the thymus, T cells having a high affinity to a self-antigen are eliminated selectively [3] . Since tumor cells arise initially from normal tissue, recognition of a tumor by T cells as a target of elimination is generally insufficient. Hence, clinical intervention, such as ex vivo manipulation of immune activation, is essential to establish an effective T cell response against tumor cells. Adoptive T cell therapy is an administration of a patient's own or donor-derived anti-tumor lymphocytes following a lymphodepleting preparative regimen [33] . Adoptive cell transfer (ACT) therapy using autologous tumor-infiltrating lymphocytes has proved to be an effective treatment for patients with metastatic melanoma. ACT can mediate objective cancer regression in approximately 50% of patients [33] . Despite the potential advantages of ACT therapy, the results of initial studies of ACT therapy using tumor infiltrate lymphocyte have indicated short persistence of the transferred cells in vivo. Note that activation of T cells must proceed with several imperative immunological steps, such as antigen presentation by antigen presenting cells with costimulation, recruitment, and activation by chemokines and cytokines. Hence, clinical intervention must achieve successful establishment of long-term immunity against cancer. In fact, recent studies have demonstrated that ACT therapy becomes more effective for enhancement of costimulation of T cells that stimulates their survival and expression in vivo, depletion of regulatory T cells and normal endogenous lymphocytes that compete with the transferred cells for homeostatic cytokines, or forced expression of a tumor-specific antigen receptor in cytotoxic T lymphocytes (CTLs) ( [31, 33] ). Mathematical models can be used to evaluate the effect of immunotherapy. Kirschner and Panetta [16] proposed a mathematical model for tumor immunotherapy by ACT with IL-2 injection. It was demonstrated that ACT, together with continuous injection of IL-2, can induce cancer regression. On the other hand, careful consideration must be given to continuous injection of IL-2. It is possible that IL-2 toxicity might result in capillary leak syndrome [33] . Another study suggests the possibility of tumor immune evasion, if continuous injection of IL-2 enhances inflammation in a tumor microenvironment [32] . In ACT therapy, a limited number of injections of ex vivo activated T cells from a patient are performed to construct antigen-specific effector cells. As described above, ACT success is dependent on the establishment of a long-sustained T cell response against tumors. It is still unknown how proliferative behavior of T cells is associated with the tumor control and eradication. Through mathematical modeling and analysis, we investigate possible outcomes of cancer immune cell interactions that could be observed after transfer of ex vivo activated T cells.
The organization of the present paper is as follows. In the next section, we introduce a simple basic mathematical model describing interactions of tumors and tumor specific CTLs. In Section 3, we investigate the consequences of CTL response against tumors under three scenarios in terms of the proliferative kinetics of CTLs. On the basis of rigorous mathematical analyses and numerical computations, we provide a mathematical classification of possible consequences of tumor immunity with biologically relevant interpretations. In Section 4, we summarize our work and suggest future directions for improvement of our modeling framework on the basis of existing experimental and clinical research.
Model formulation
We assume that tumor killing is mediated by effector CD8 positive T cells, called cytotoxic T lymphocytes (CTLs). A tumor is removed not only by CTLs but also by natural killer (NK) cells that specifically kill MHC class I down-regulated tumors. In this paper, we concentrate on tumor killing by CTLs. An immune response against tumors can be regarded as a predator-prey interaction [10] . The classical Lotka-Volterra prey-predator system has been used extensively to describe such interactions. In this paper, we extend the classical Lotka-Volterra prey-predator system to describe interactions between tumors and CTLs. We will use the term "proliferation" to refer to CTL population growth via clonal expansion. Once dendritic cells (DCs) and helper T cells are activated, CTLs can proliferate with the help of those cells. We consider an ideal situation in which the essential events required for clonal expansion of CTLs, such as antigen presentation from antigen-presenting cells (APCs) with costimulation, have already been sufficient and equipped. Since killing of tumors is generically less effective without ex vivo activation of T cells, substantial tumor killing by CTLs begins after CTL injection. Let x and y denote the concentrations of tumors and transferred CTLs, respectively, at the present time t. We assume that in the absence of immunity, the population growth of tumor cells is governed by logistic growth with intrinsic growth rate r and carrying capacity K. Tumor cell elimination by CTLs follows the mass action law with constant γ. CTL clonal expansion triggered by the presentation of tumor-derived antigen is described by αxy, where α is the antigen-dependent clonal expansion rate per unit of tumor cells. We assume further that CTLs undergo antigen-independent proliferation, also referred to as programmed proliferation [6] . In this paper, three distinct types of function are adopted to formulate programmed proliferation of CTLs explicitly. Let m denote the maximum CTL proliferation rate. To incorporate nonlinear effects in programmed proliferation, the function describing the programmed proliferation rate p(y) is normalized to ensure that the value of p(y) is between zero and one. The CTL proliferation limit arises naturally from, for example, limited availability of APC binding sites or an autocrine signaling saturation effect. These assumptions are discussed in more detail in each subsection of Section 3. Note that killing of tumors by CTLs can be impaired not only by cell death but also by inactivation. Let μ be the density-independent CTL inactivation rate. In this paper, activation-induced cell death (AICD) is formulated simply as a quadratic nonlinear term with proportional constant δ, namely, δy 2 .
The primary mathematical model is described by the following system of differential equations.
The biologically feasible initial values lie in the following nonnegative cone:
In the following section, we investigate the dynamics of (1) with (2) by changing the explicit form of the function p(y). More precisely, we consider the following explicit forms for p(y): The first form represents constant CTL proliferation. In addition to constant proliferation, p 2 (y) postulates the existence of density-dependent negative feedback, as exemplified by competition among CTLs for APC binding sites. The third type of proliferation function p 3 (y) incorporates a densitydependent positive feedback mechanism derived from autocrine/paracrine proliferation mediated by self-reproducing cytokines. Let us introduce a well-known concept in immunology. Anergy is the phenomenon in which immune cells become or remain inactive despite the presence of antigen. In this paper, we call the CTL response anergic, if the activated CTL concentration is zero in the presence of a tumor.
Mathematical analyses and computation

Proliferation without feedback
In this subsection, we consider a special case of (1) in which no density-dependent feedback is present in p(y):
(3) is inferred from (1), if p(y) = p 1 (y) ≡ 1. The explicit form of p 1 (y) indicates that T cell maintenance is mediated by antigen-independent survival signals. If m − μ < 0, then (3) corresponds to the classical Lotka-Volterra prey-predator system. Complete classification of the dynamics for the classical Lotka-Volterra prey-predator system has already been obtained [11] . A boundary equilibrium (K, 0) at which only prey is present is globally asymptotically stable, if there is no interior equilibrium.
An interior equilibrium is globally asymptotically stable, whenever it exists in the positive cone. To examine the effect of CTL proliferation, we assume henceforth that m − μ > 0. Although no novel mathematical results are derived in this subsection, we need to show the mathematical expressions explicitly to obtain proper biological interpretations. Biological interpretations of mathematical results for (1) in terms of tumor-immune interactions are not obvious in the classical Lotka-Volterra system.
Equilibria
There are four possible equilibria. Naive equilibrium E n = (0, 0) and anergic equilibrium E a = (K, 0)
is an interior equilibrium of (3). It follows from the first equation of (3) that
By definition, x * 1 > 0 and y * 1 > 0. This yields
Substituting (4) into the second equation of (3) yields 
Detailed biological interpretations to δ * and μ * are introduced in subsection 3.1.3. By (7), (6) can be rewritten as y *
Note that the condition (5) is equivalent to
Equilibria stability
We derive conditions for local asymptotic stability of equilibria. It is easy to see that naive equilibrium E n is always unstable. The characteristic equation defined for the linearized equations of (3) around anergic equilibrium E a is given by
Since m > μ, the stability of E Finally we derive the characteristic equation for E p 1 . It is given by
Since the coefficients of λ and the constant term of (9) are positive, E p 1 is locally asymptotically stable whenever it exists. Applying planar dynamical systems theory, we found that E p 1 is globally asymptotically stable (Appendix A). The dynamics exhibited by (3) are summarized in Table I . Table I . Existence and stability conditions for equilibria of (3).
existence
(global) stability naive:
* < m and γȳ 1 − r < 0 always stable
Summary and interpretations
It is easy to see thatȳ 1 is strictly increasing with respect to m. As the maximum proliferation rate m increases, the dynamics of (3) anergic is stable, if γȳ 1 −r > 0. We also see that the sign of γȳ 1 −r defines the re-emergence of tumor. Assume a situation in which ACT therapy has successfully eliminated a majority of tumor cells, but a small portion of tumor cells persists. Then, surviving tumor cells can grow exponentially with the intrinsic growth rate r in the absence of CTLs. However, pressure from CTLs persists after ACT therapy. The term γȳ 1 represents the pressure from CTLs on tumor cells. Hence, tumors can successfully re-emerge, if the intrinsic tumor growth rate r is greater than the CTL pressure, namely, γȳ 1 − r < 0. On the other hand, the cure state remains stable, if the CTL pressure exceeds the intrinsic tumor growth rate: γȳ 1 − r > 0. We see that the re-emergence condition can be understood as the efficacy of tumor vaccination: prevention of the re-emergence of tumor corresponds exactly to the strategy of cancer vaccination by establishing a long-sustained memory T cell response.
Proliferation with negative feedback
The specific mathematical model to be considered in this subsection is given by
Effective CTL proliferation via clonal expansion is mediated by the help of antigen presentation from dendritic cells (called cross-presentation) and Th1-type cytokines secreted by Type I helper cells such as IL-2 and IFN-γ. In this subsection, we take into account the effect of competition between CTLs for APC binding sites expressed on the surface of dendritic cells. Competition of this kind operates to interfere with the growth of CTLs at the population level. This interference effect could be formulated as p 2 (y) = 1 h+y , following the well known Beddington-DeAngelis functional response [1, 2] . Note that the proliferation term m h+y y is replaced by a constant input m, if h = 0. On the other hand, the proliferation term p 2 (y) → 0 as h → ∞. At the limit, (11) corresponds to the classical Lotka-Volterra prey-predator system. In this subsection, we investigate the effects of competition among CTLs and compare the results with those obtained in the previous subsection.
Equilibria
There are four equilibria of (11)
. To obtain existence conditions for cure equilibrium, we consider the following quadratic function, derived from the second equation of (11):
It follows that q c 2 (y) = 0 has exactly one positive root, if
In contrast, q c 2 (y) = 0 does not have any positive real roots, if hμ > m. For persistent equilibria, it follows from the first equation of (11) that in the steady state
Since the concentrations of surviving tumor and active CTLs must be positive, we require x * 2 > 0 and
Substituting (14) into the second equation of (11) gives the quadratic function
Assume that hμ * < m. Since (15) must hold, q 
Next we assume that hμ * > m. We can show that the discriminant of (16) is strictly positive. We claim that q p 2 (y) = 0 has no positive real root. In fact, the condition hμ * > m can be rewritten as
To have positive real roots, the axis of symmetry of (16) must satisfy hδ * + μ < αK. However, this contradicts (18) . Hence, there exists exactly one persistent equilibrium, if hμ * < m and γȳ 2 − r < 0.
Equilibria stability
We now investigate the local stability of equilibria E n , E a , E 
By using the equality −μ − δȳ 2 
Hence E p 2 is locally asymptotically stable whenever it exists. Moreover we can show that E p 2 is globally asymptotically stable (Appendix A). A classification of the dynamics exhibited by (11) is given in Table II .
Advantages of competition
It follows from (12) thatȳ 2 is strictly increasing with respect to m. The dynamics of (11) 
Note that existence and stability conditions for equilibria of (3) correspond to those of (1) in subsection 3.1, provided that we regard the weighted inactivate rate hμ in this subsection as the conventional inactivation rate μ in subsection 3.1. Tumor clearance is established, if hμ < m. This condition is likely to hold if h & μ are small or m is large. Tumors become persistent, if clearance is not sufficient, in the sense that γ satisfies γȳ 2 − r < 0. For fixed γ and r, clearance of tumor therefore requires not only a high proliferation rate m, but also a high CTL population level without any activation from tumors. We investigate whether competition among CTLs can have an advantageous effect in eradicating tumors. The activated CTL population size in the cure state can be used as a measure to evaluate the effectiveness of immune responses. More precisely, two values,ȳ 1 defined for (3) andȳ 2 defined for (11) , are compared. Ifȳ 1 >ȳ 2 , we regard competition as deleterious in CTL proliferation; if y 1 <ȳ 2 , competition is regarded as advantageous. To investigate this criterion, we substituteȳ 1 into q 
This implies that competition among CTLs operates to refine pressure against tumor cells. In other words, competition is advantageous, if (i) density-independent population growth rate m − μ is small, (ii) the negative density-dependent effect measured by δ is large, and (iii) h is small. Note that for sufficiently small h,
This implies that competition among CTLs regulates the supply of activated CTLs as a constant input, if h 1. This regulation is expected to suppress over-proliferation of CTLs, leading to suppression of excessive inactivation of CTLs via activation-induced cell death. As a result, competition among CTLs can be advantageous.
Proliferation with positive feedback
The explicit form of p 3 (y) = my h+y can be derived from the quasi-steady state approximation for autocrine signaling mediated by self-secreting cytokines. A commonly known example for autocrine/ paracrine proliferation is clonal expansion of CTL via IL-2 activation. We do not distinguish autocrine and paracrine in the population dynamics. Let c(t) denote the concentration of IL-2 secreted by CTLs themselves. The interaction between CTL and IL-2 is described by the following equations:
c (t) = ky(t) − dc(t), y (t) = m c(t) h + c(t) y − (μ + δy(t))y(t).
We assume that the dynamics of IL-2 is very fast compared to the population dynamics of CTLs. Thus, the quasi-steady state approximation for the dynamics of IL-2 yields c(t) = ky(t)/d Substituting this approximated c(t) into the second equation of (23) yields the second equation of (22) without the effect of activation from tumors. (22) corresponds to (3) if h = 0. On the other hand, p 3 (y) → 0 as h → ∞, implying that the dynamics of (22) is expected to behave similarly to the classical Lotka-Volterra prey-predator system, if h is either small or sufficiently large. In this subsection, we investigate how autocrine/paracrine proliferation affects the dynamics generated by tumor-CTL interactions.
Equilibria
The main difference from subsections 3.1 and 3.2 is that (22) admits multiple cure and persistent equilibria. Naive equilibrium E n = (0, 0) and anergic equilibrium E a = (K, 0) are again steady states of (22) . To investigate existence conditions for cure equilibrium, we consider the quadratic function which is derived from the second equation of (22):
In contrast to subsection 3.2, q 
and the discriminant satisfies
Defineμ byμ = μ + hδ + 2 √ hδμ. (25) and (26) 
Letȳ 3,S andȳ 3,N (ȳ 3,S <ȳ 3,N ) denote two positive roots of q c 3 (y) = 0. The subscripts "S" represent "saddle" and "node", respectively. Note that (27) holds for sufficiently large m.
We now derive existence conditions for persistent equilibria. In the manner similar to that shown in subsection 3.2, we consider the following quadratic function
There are two possible cases depending on the sign of μ * . First, we assume that μ * < 0. In this case, there exists exactly one positive real root of q (27) holds. In a manner similar to that of subsection 3.2, we obtain that
Next we assume that μ * > 0. q 
and (30), we obtain
Equilibria stability
Occurrence of multiple cure and persistent equilibria suggests bistability between the two equilibria. The characteristic equation for naive equilibrium E n is
Thus E n is always unstable, but it is stable in the y-axis direction. The characteristic equation for anergic equilibrium E a is given by
Hence E a is locally asymptotically stable, if μ * > 0. To investigate the local stability of cure equilibria, it is necessary to assume that (27) holds. For notational convenience, we do not distinguishȳ 
Substituting the left hand side of q c 2 (y) = 0 into the last equality of (35) yields
is the axis of symmetry of q We shall denote the components of persistent equilibria without subscript: x * and y * . The characteristic equation for persistent equilibria is given by
where
c 2 is given by
With the same procedure as for the derivation of the second equality of (35), c 2 becomes
Note that the coefficient of λ is
Although we cannot obtain explicit conditions, the first equality of (36) implies that a > 0 for sufficiently small h or m. For the constant term of the characteristic equation, straightforward calculation yields that
Substituting the right hand side of q p 3 (y) = 0 into b gives
where are drawn with the set of parameters (40) 
Tumor immune escape
We investigate the possibility of tumor cell immune escape as simple evolutionary dynamics. Two parameters r and K, representing the intrinsic tumor growth rate and carrying capacity, respectively, are regarded as variable traits. Selection would favor tumors having a trait from which these tumors can replicate more than usual under the presence of immune pressure. It is expected that a high intrinsic growth rate r would operate to assist tumor persistence. Consider a situation in which most tumor cells have already been removed by surgery or other clinical treatments. Transfer of ex vivo stimulated T cells is then conducted to eradicate tumors. Hence, we consider a low concentration of tumor and T cells at the initiation of the transfer therapy.
We use the following set of parameters: the cure state immediately becomes unstable (right panel of Fig. 2 ). Hence the strategy of increasing replication ability supports the re-emergence of tumor cells even if immune pressure is present. Since anergic state E a is unstable, CTLs never become anergic in this case, because the intrinsic CTL population growth rate is positive: αK − μ > 0. Using stability analyses, we found that an anergic state is always locally stable, if μ * = μ > αK.
In terms of tumor traits, μ − αK > 0 is likely to hold when K is small. In this situation, the intrinsic CTL growth rate is negative. Therefore, it is expected that an advantageous strategy for tumors would be to decrease carrying capacity K. Numerical simulations were implemented to confirm this expectation. K is gradually decreased from 5.0 to 3.0 (K = 5.0, 4.5, 4.0, 3.5, 3.0) to obtain μ geαK. Gradual decline of K can be thought as an emergence of a mutant tumor. In numerical simulation, a succesive mutations during the therapy is incorporated as sudden change of K every time period Δt = 25. A trajectory for the complete clearance of tumors is again depicted on the left panel of Fig. 3 for comparison. For the case of decreased carrying capacity, CTLs finally settle into an anergic state (right panel of Fig. 3 ). Decreasing carrying capacity K would be more advantageous for tumor cells than increasing intrinsic growth rate r. Note that the anergic state is locally stable, whenever 
Discussion
We studied three specific models for tumor-CTL interactions that differ in the formulation of CTL proliferation kinetics. On the basis of rigorous mathematical and computational analyses, dynamics classification implies four possible outcomes at the steady state, naive (no tumor and immune response), anergic (no immune response in the presence of tumors), persistence (survival of tumors in the presence of an immune response) and cure (eradication of tumors by a sustained immune response). The maximum CTL proliferation rate is a good measure for checking possible transitions from anergic, through persistence, to cure states. Two scenarios (no feedback in subsection 3.1 and negative feedback in subsection 3.2) exhibit qualitatively identical results. Negative feedback can be beneficial to tumor elimination, when AICD is strong, to suppress CTL activation. It was suggested in subsection 3.4 that CTL response can suddenly collapse, leading to tumor escape from an immune response, when tumor cells evolve to decrease the carrying capacity. A biologically possible scenario is to shrink or restrict the volume of solid tumors. In Figs. 2 and 3 , a numerical simulation result for tumor immune escape is shown. Tumors become persistence if the replication rate r increases. Tumor immune escape can occur as well if tumors gradually decrease the carrying capacity K. Reduction of antigenic stimulation from tumors would lead to inactivation of CTLs to be anergic. Note that there exists a possibility of the failure of CTL activation due to insufficient antigenic stimulation from tumors despite the presence of the possibility of CTL activation (Fig. 1) . We investigated the possibility of tumor immune escape for the third scenario: positive feedback CTL proliferation. Although sudden failure of CTL responses is a particular phenomenon for the third senario, a similar result in subsection 3.4 would be obtained for the other scenarios (subsections 3.1 and 3.2) when the carrying capacity K gradually decreases. Although the effects of adoptive cell transfer therapy have already been examined in a mathematical model by Kirschner and Panetta [16] , complete tumor regression is mediated by continuous injection of effector cells and IL-2. Our model proposes another possibility for tumor regression by a limited infusion of activated T cells, as long as the T cells can still undergo self-renewal proliferation. Establishment of memory T cells is the major aim of the transfer, since proliferation, long-term survival, and sustainable immune response are expected. Recently, an experimental study succeeded in producing long-lived antitumor CD8 positive lymphocytes generated by artificial antigen-presenting cells that are expected to mediate a long-term immune response [17] . Incorporation of more detailed diverse known interactions between tumor cells and immune cells is required for mathematical modeling to obtain comprehensive understandings regarding ACT.
Cell mediated immunity supported by effector T cells is considered as particularly important for eliciting an immune response to tumors. Somatic evolution of cancer confers the ability to create a microenvironment in which the host immune system becomes tolerant or is even impaired by the escape mutants of tumors via immunosuppressive factors. Some tumor cells can secrete TGF-β, which is used as an immunosuppressive factor to prevent attack from the immune system (for an example for prostate cancer, see [30] ). Various possible routes for evading an immune response have been reported ( [24, 25] ). The mathematical results obtained in this paper suggest the possibility of immune escape. Down-regulation of the expression of MHC class I molecules would be beneficial for tumors to reduce antigenic stimulation to CTLs (cf., [25] ). Exhausted effector cells are likely to undergo apoptosis via expressing a PD-1 receptors, which is generally known to overwhelm a CTL defense. It was noted that PD-L1 is expressed by distinct tumor types and promotes apoptosis of effector CTLs. These important mechanisms promoting immune escape of tumor cells are not considered within the modeling framework. Immune escape of tumors by adaptation can be studied more properly in the framework of evolutionary dynamics ( [18, 19] ). This work is left for future consideration.
